Nexus Pharmaceuticals v. Somerset Pharma: Ephedrine Patent Infringement Case Transferred to Camden Division
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Nexus Pharmaceuticals, Inc. v. Somerset Pharma, LLC et al. |
| Case Number | 3:23-cv-01248 (Newark) / 1:23-cv-01248 (Camden) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | March 2023 – March 2024 391 days in Newark |
| Outcome | Case Transferred – Infringement Active |
| Patents at Issue | |
| Accused Products | Somerset Ephedrine-based Pharmaceutical Compositions |
Case Overview
The Parties
⚖️ Plaintiff
A specialty pharmaceutical company focused on sterile injectable and hospital-use drug products, holding patents on proprietary formulations.
🛡️ Defendant
Operates in the generic and specialty pharmaceutical space, producing ephedrine-based pharmaceutical compositions.
The Patents at Issue
This dispute centers on two U.S. patents protecting ephedrine-based pharmaceutical compositions. These types of patents are crucial in the specialty pharma sector, extending IP protection beyond the active pharmaceutical ingredient (API) to specific formulations or manufacturing processes.
- • U.S. Patent No. 11,426,369 B2 — Compositions comprising ephedrine or an ephedrine salt and methods of making and using same.
- • U.S. Patent No. 11,478,436 B2 — Further compositions comprising ephedrine or an ephedrine salt and methods thereof.
Developing an ephedrine product?
Check if your pharmaceutical formulation might infringe these or related patents before commercialization.
The Verdict & Legal Analysis
Outcome and Procedural History
The case, initially filed in the Newark division as 3:23-cv-01248, was active for approximately 391 days before its administrative transfer to the Camden division on March 28, 2024. It now continues as 1:23-cv-01248. This transfer was a procedural re-assignment within the District of New Jersey, not a merits-based ruling. The core infringement action remains live and unresolved.
Legal Significance
The **U.S. District Court for the District of New Jersey** is a prominent venue for pharmaceutical patent litigation, handling numerous cases involving drug formulations. This case, focused on ephedrine compositions, reflects a growing trend where specialty pharmaceutical companies leverage recently issued formulation patents to defend their market positions for established APIs. The procedural transfer to Camden does not diminish the legal significance of the underlying infringement claims, which will proceed to address issues of literal infringement, doctrine of equivalents, and potential invalidity challenges.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical formulation. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in ephedrine formulations
- Understand claim construction patterns for composition patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical composition.
- Input your formulation details or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Specific ephedrine salt compositions
2 Active Patents
Asserted in this case
Design-Around Options
Possible with careful formulation
✅ Key Takeaways
New Jersey remains a preferred venue for pharmaceutical formulation patent assertions; venue selection within the district (Newark vs. Camden) carries practical litigation implications.
Search related case law →Asserting paired composition and method patents maximizes claim coverage and infringement exposure for defendants.
Explore precedents →The case is substantively active post-transfer; monitor Camden docket 1:23-cv-01248 for Markman and dispositive motion developments.
Track litigation progress →Pharmaceutical companies should audit competitor patent portfolios for recently issued formulation patents covering established APIs.
Conduct competitive intelligence →Multi-entity defendant structures require coordinated IP defense strategies across related corporate entities.
Analyze corporate structures →Frequently Asked Questions
The case involves U.S. Patent Nos. 11,426,369 B2 and 11,478,436 B2, both covering compositions comprising ephedrine or an ephedrine salt and related methods.
On March 28, 2024, the case was administratively transferred from the Newark vicinage to the Camden division of the District of New Jersey. It continues under case number 1:23-cv-01248.
A merits ruling on these formulation patents could influence how courts interpret claim scope for second-generation pharmaceutical composition patents covering long-established APIs.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Center – US11426369B2
- USPTO Patent Center – US11478436B2
- PACER – District of New Jersey
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.